Experienced in Primary Intestinal Lymphangiectasia

Dr. Margarita M. Nunez

Physiatry
475 Seaveiw Avenue, 
Staten Island, NY 
Experienced in Primary Intestinal Lymphangiectasia
475 Seaveiw Avenue, 
Staten Island, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Margarita Nunez is a Physiatrist in Staten Island, New York. Dr. Nunez is rated as an Experienced provider by MediFind in the treatment of Primary Intestinal Lymphangiectasia. Her top areas of expertise are Chronic Subdural Hematoma, Subdural Hematoma, Stroke, and Hemiplegia.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Physiatry
Licenses
Physical Medicine & Rehabilitation in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

475 Seaveiw Avenue, Staten Island, NY 10305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: December 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers
Enrollment Status: Completed
Publish Date: January 16, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

2 Total Publications

Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 22, 2016
Similar Doctors
Distinguished in Primary Intestinal Lymphangiectasia
Dr. Kathleen D. Francis
Physiatry
Distinguished in Primary Intestinal Lymphangiectasia
Dr. Kathleen D. Francis
Physiatry
200 South Orange Ave, 
Livingston, NJ 
 (19.2 miles away)
973-322-7366
Languages Spoken:
English
See accepted insurances

Kathleen Francis is a Physiatrist in Livingston, New Jersey. Dr. Francis is rated as a Distinguished provider by MediFind in the treatment of Primary Intestinal Lymphangiectasia. Her top areas of expertise are Lymphedema, Meige Disease, Primary Intestinal Lymphangiectasia, and Lymphangiectasis.

Distinguished in Primary Intestinal Lymphangiectasia
Dr. Kwan-iong L. Jakobsen
Physiatry
Distinguished in Primary Intestinal Lymphangiectasia
Dr. Kwan-iong L. Jakobsen
Physiatry

Westbury Medical Care PC

355 Post Ave, 
Westbury, NY 
 (28.9 miles away)
516-333-3253
Languages Spoken:
English
See accepted insurances

Kwan-iong Jakobsen is a Physiatrist in Westbury, New York. Dr. Jakobsen is rated as a Distinguished provider by MediFind in the treatment of Primary Intestinal Lymphangiectasia. Her top areas of expertise are Lymphedema, Meige Disease, Primary Intestinal Lymphangiectasia, and Lymphangiectasis.

Distinguished in Primary Intestinal Lymphangiectasia
Dr. Mously A. Le Blanc
Physiatry
Distinguished in Primary Intestinal Lymphangiectasia
Dr. Mously A. Le Blanc
Physiatry

National Health Rehabilitation LLC

1339 York Ave, 
New York, NY 
 (14.4 miles away)
201-654-5397
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Mously Le Blanc is a Physiatrist in New York, New York. Dr. Le Blanc has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Primary Intestinal Lymphangiectasia. Her top areas of expertise are Lymphedema, Primary Intestinal Lymphangiectasia, Meige Disease, and Lymphangiectasis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nunez's expertise for a condition
ConditionClose
        View All 13 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile